massimo iavarone

Join Lars Aabakken, @MarcoMarzioni74, @JulieHeimbach, and @SaborowskiAnna as they explore key updates from the EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma (eCCA) Register below👇👇 @JHepatology @NaultJc @FrancqueSven #LiverX

Original Article Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction Van Kleef et al. #LiverX journals.lww.com/hep/abstract/2…

Artículo Original Comparación de la precisión diagnóstica y la utilidad de pruebas no invasivas para enfermedad hepática clínicamente significativa en una población general con disfunción metabólica Van Kleef et al. #LiverX journals.lww.com/hep/abstract/2…

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA Phase 3 randomized clinical trial by Lau et al #HepHighlights journals.lww.com/hep/citation/2…

Plasma exchange in ACLF- 😎 Improved short term survival ❗️Tolerance was an issue 🤔90-day survival was similar 🟥Infections are a cause for concern Only a bridge to transplant? @aiims_newdelhi @drshalimar @AASLDtweets @BavenoCoop @EASLnews @INASL_Liver @ShekharSwa9790

Missed #BavenoVIII and feeling some regret? No worries… This Wednesday, a new episode of Talk Liver to Me drops 🎙️@tom_marjot, @MattiasMandorf1 & Cristina Ripoll unpack the key takeaways from #BavenoVIII 🔗 easl.eu/event/baveno-v… #LiverTwitter #LiverX

Original Article Simulating the impact of survival benefit-based liver transplant organ allocation Goldberg et al. #LiverX shorturl.at/YUjtp

❓ Do all Child-Pugh B HCC patients respond similarly to Atezolizumab + Bevacizumab? @LiverInt 👉 Even within Child-Pugh B, patients with better liver reserve (mALBI ≤2b) showed relatively better outcomes with Atezo + Bev compared with those with mALBI grade 3 (mPFS: 5.5mo vs. 1.9mo, p=0.004; mOS: 10.8mo vs. 7.3mo, p=0.024). @ILCAnews @EASLnews @myESMO @ASCO 👉 A retrospective study by Sasaki et al. has recently been published in Liver International. Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B Full text: DOI: 10.1111/liv.70466

⌛️Less than an hour to go! There's still time to join this EASL #DeepDive on the new #HBV Guidelines! @JHepatology

What’s next in #HBV management? Join this week's #EASLDeepDive for insights into emerging therapies, evolving nomenclature, and future directions shaping patient care. 👇More info and registration below @FrancqueSven @manna_555 @Massimoiava #LiverX

🚨 Our study is now published! @j_livercancer 👉Organ-specific irAE landscape across phase III trials in advanced #HCC 👉 Hepatic toxicity remains the most frequent irAE @ILCAnews @myESMO @ASCO @EASLnews #LiverCancer #Immunotherapy #Toxicity #Hepatitis

Proud to be part of three Lancet papers arriving the next month. First topic: PSC - of course (always first)! Online link: authors.elsevier.com/c/1moe3V-4XSkqY

Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma @HEP_Journal doi.org/10.1097/HEP.00… 👏Timely guideline 👉still very difficult to treat tumor @ASCO @myESMO @EASLnews @ILCAnews

New Talk Liver to Me podcast episode is out now! Experts @MattiasMandorf1, @MarcoSanduzzi and @LorenzaRimassa discuss the strengths and limitations of the BCLC model in an era of rapidly evolving systemic therapies and personalised care, sharing real-world examples of when the algorithm helps and when clinical practice diverges. Listen on Apple Podcasts: podcasts.apple.com/us/podcast/tal… Listen on Spotify: open.spotify.com/episode/3yFFME… Watch on EASL Campus: easlcampus.eu/tltm/episode-05 #LiverTwitter #LiverX

Not to miss!!

Identificata una possibile terapia efficace per la sindrome di Leigh, una grave malattia mitocondriale pediatrica finora priva di trattamenti efficaci. A dirlo uno studio internazionale a cui ha collaborato la Statale. 👉lastatalenews.unimi.it/sindrome-leigh…

HepB-CpG vaccination: An alternate strategy to lifelong antiviral therapy in patients transplanted for chronic hepatitis B journals.lww.com/lt/abstract/99…

🚨 Key insights from An International Multicentre Study with Prof. #ThomasYau ! @LiverInt @ILCAnews 👉  Nivo/Ipi shows clinically meaningful efficacy even after prior Ate/Bev in advanced HCC. 👉 Although Nivo/Ipi after Ate/Bev showed a lower ORR (20.0%) compared to ICI-naïve patients (42.6%), 👉 The Duration of Response (DoR) was highly comparable (23.7 vs. 24.8 months)! @myESMO @ASCO @EASLnews Full text: doi.org/10.1111/liv.70… #HCC #LiverCancer #Immunotherapy #Nivolumab #Ipilimumab #Oncology

EASL is deeply saddened by the loss of Dr Ahmed Elsharkawy, consultant transplant hepatologist, researcher, educator and valued member of the EASL Governing Board. Ahmed served EASL with honesty, courage and a deep commitment to the community he cared so much about. He was never afraid to speak up when it mattered, always guided by a strong sense of fairness and integrity. His leadership helped shape important initiatives that will continue to benefit the liver community for years to come. Beyond his professional achievements, Ahmed will be remembered for his warmth, humour and generosity as a colleague and friend. Our thoughts are with his wife Sarah, his children, his family and all those who knew and worked with him. @DebbieShawcros1 @analleo

⏳ Final countdown: 3 weeks to #BavenoVIII‼️ 9⃣ expert panels across the full PH spectrum — from risk stratification in cACLD to decompensation prevention/management, bleeding, recompensation & vascular liver disorders 🗓️ 27-28 March-🧒29/03 🔗 baveno8.org 📄 👇